Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 41715239 · doi:10.1186/s40842-025-00270-4
What was done
A PRISMA-compliant systematic review and meta-analysis (PROSPERO CRD420251229397) of placebo-controlled phase 2 and phase 3 trials evaluating the oral small-molecule GLP-1 receptor agonist orforglipron. Random-effects models were used to pool mean differences and risk ratios with 95% confidence intervals across four included trials.
What was found
Across 4 trials, orforglipron significantly improved modifiable cardiovascular risk factors compared with placebo: body weight decreased by -6.08% (95% CI -7.68 to -4.47; up to -9.31% at higher doses), HbA1c decreased by -0.85% (95% CI -1.53 to -0.18; up to -1.36%), systolic blood pressure decreased by -4.32 mmHg (95% CI -5.61 to -3.03; up to -5.78 mmHg at 45 mg), LDL-cholesterol decreased by -4.14% (95% CI -6.38 to -1.91), triglycerides decreased by -10.90% (95% CI -14.36 to -7.43), VLDL-cholesterol decreased by -10.81% (95% CI -14.10 to -7.51), and HDL-cholesterol increased by +3.31% (95% CI +1.66 to +4.97). Heterogeneity was absent (I² = 0%) for systolic blood pressure and all lipid outcomes. Gastrointestinal side effects were elevated: nausea (RR 5.22), vomiting (RR 3.24), and eructation (RR 6.80).
Why it matters
Orforglipron demonstrates that an oral small-molecule GLP-1 receptor agonist can achieve cardiometabolic risk factor reductions comparable to injectable formulations, providing an alternative for patients with injection hesitancy.
Limits
The review included only four trials, and the total participant count is not reported in the abstract. Measured endpoints were surrogate cardiovascular biomarkers rather than hard clinical outcomes like major adverse cardiovascular events (MACE) or mortality. All trials were placebo-controlled without active comparisons to injectable GLP-1 receptor agonists.
Cited by
- supports Orforglipron is a non-peptide GLP-1 receptor agonist.